Skip to main content
Smart Investors Daily
CG

NASDAQ · CGEM

Cullinan Therapeutics, Inc.

Healthcare · Medical - Pharmaceuticals

$9.07

Up+$0.06 (+0.67%)

Updated Nov 20, 2026, 2:38 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
730.18M
P/E ratio
-3.35
Dividend yield
0.00%
52-week range
$8.23 – $23.19
Volume
1M
Avg. volume
1.2M

Price performance · CGEM

CGEM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

CGEM closed at $9.07 after 21 trading sessions, down 39.21% for the selected period.

Last close
$9.07
Period change
-39.21%
Period low
$9.01
Period high
$15.75
Daily close
View OHLC price history
CGEM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$9.08$9.30$8.53$9.071M
Nov 18, 2026$9.24$9.5144$8.81$9.011.06M
Nov 17, 2026$9.45$9.45$8.47$9.2751.63M
Nov 16, 2026$10.11$10.2752$9.46$9.50866.74K
Nov 13, 2026$10.19$10.345$9.75$10.281.38M
Nov 12, 2026$11.04$11.12$10.105$10.191.14M
Nov 11, 2026$11.34$11.675$11.15$11.35985.83K
Nov 10, 2026$11.71$12.04$10.95$11.23810.43K
Nov 9, 2026$11.40$12.41$10.795$11.731.04M
Nov 6, 2026$11.09$11.77$10.6901$11.31755.71K
Nov 5, 2026$12.36$12.475$10.77$10.801.79M
Nov 4, 2026$15.99$16.285$11.92$12.492.2M
Nov 3, 2026$15.04$16.20$14.975$15.75788.71K
Nov 2, 2026$15.13$15.345$14.63$14.93730.77K
Oct 30, 2026$15.38$15.72$14.7001$15.03389.41K
Oct 29, 2026$15.60$16.185$15.35$15.45460.06K
Oct 28, 2026$14.93$15.6163$14.72$15.56594.32K
Oct 27, 2026$14.66$14.98$14.28$14.84488.23K
Oct 26, 2026$14.71$14.87$14.39$14.54438.58K
Oct 23, 2026$14.945$14.945$13.86$14.37485.2K
Oct 22, 2026$14.82$15.32$14.64$14.92392.65K

Latest CGEM news

The latest Smart Investors Daily articles mentioning CGEM.

CGEM research

Overview

Company profile and research snapshot.

Company profile

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$32.67
Implied upside
—
Analysts
17
CGEM recent ratings
DateFirmRatingTarget
Nov 11, 2026WedbushOutperform—
Oct 28, 2026BTIGBuy—
Oct 19, 2026BTIGBuy—
Oct 2, 2026HC Wainwright & Co.Buy—
Sep 25, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLCCAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced their partner Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.